Apellis Pharma…
ProfileJobs

Apellis Pharmaceuticals

Suggest Edit
    • Healthcarebiotechdrug developmentpharma
    Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
    Market capitalization(2018-09-21)
    $1.1 B
    TypePublic
    HQCrestwood, US
    Founded2008
    Size (employees)32 (est)
    Websiteapellis.com
    Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Apellis Pharmaceuticals

    Cedric Francois

    Cedric Francois

    President and CEO
    Mike Yeadon

    Mike Yeadon

    Chief Scientific Officer
    Pascal Deschatelets

    Pascal Deschatelets

    Founder & Chief Operating Officer
    Show more

    Apellis Pharmaceuticals Office Locations

    Apellis Pharmaceuticals has offices in Waltham, Cambridge, San Francisco and Crestwood
    Crestwood, US (HQ)
    6400 Westwind Way
    Cambridge, US
    1218 Massachusetts Ave
    San Francisco, US
    300 41 Grant Ave
    Waltham, US
    200 5th Ave
    Show all (4)
    Report incorrect company information

    Apellis Pharmaceuticals Financials and Metrics

    Apellis Pharmaceuticals Revenue

    USD

    EBIT (Q2, 2018)

    		(54.9 m)

    Market capitalization (21-Sep-2018)

    		1.1 b

    Closing stock price (21-Sep-2018)

    		19.9

    Cash (30-Jun-2018)

    		253.8 m
    Apellis Pharmaceuticals's current market capitalization is $1.1 b.
    Annual
    USDFY, 2017

    Cash

    		175.6 m

    Current Assets

    		182 m

    Total Assets

    		182.1 m

    Accounts Payable

    		3.7 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Cash

    		152.9 m253.8 m

    Current Assets

    		163.1 m266.7 m

    Total Assets

    		163.2 m266.8 m

    Accounts Payable

    		4.6 m5.1 m
    show all
    Annual
    USDFY, 2017

    Net Income

    		(51 m)

    Accounts Payable

    		932.3 k

    Cash From Operating Activities

    		(46.6 m)

    Cash From Financing Activities

    		197.4 m
    Quarterly
    USDQ1, 2018Q2, 2018

    Net Income

    		(21.7 m)(55.1 m)

    Accounts Payable

    		921.8 k1.5 m

    Cash From Operating Activities

    		(22.9 m)(53.6 m)

    Cash From Financing Activities

    		222.7 k131.8 m
    show all
    USDY, 2018

    Financial Leverage

    		1.2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    MyoKardia
    Healthcare - Public
    Athersys
    Healthcare - Public
    Otonomy
    Healthcare - Public
    Ironwood Pharmaceuticals
    Healthcare - Public
    Compare competitors

    Apellis Pharmaceuticals Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Apellis Pharmaceuticals News and Updates

    September 04, 2018

    Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy

    PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™
    July 31, 2018

    Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results

    - Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 -
    June 27, 2018

    Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow

    Report incorrect company information

    Apellis Pharmaceuticals Company Life and Culture

    Report incorrect company information
    Download PDF